Novo Nordisk rolls out weight loss drug Wegovy in India, following Eli Lilly’s Mounjaro launch

June 24, 2025 02:04 AM PDT | By EODHD

Google News:

Novo Nordisk rolls out weight loss drug Wegovy in India, following Eli Lilly’s Mounjaro launch — Image source: Kalkine Media

Recent News

Oil prices face litmus test as US-Iran nuclear talks, OPEC meeting to...

Brent crude oil price forecast ahead of OPEC+ meeting

Enjoy Pokémon Go Fest Global With Anyto: Best Pokémon Go Spoofer, Now...

Equinix (NASDAQ:EQIX) Updated in Nasdaq Composite Sector

[New Nordisk] hapabapa/iStock Editorial via Getty Images Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) has launched its blockbuster weight-loss drug Wegovy in India, shortly after rival Eli Lilly (NYSE:LLY [https://seekingalpha.com/symbol/LLY]) introduced its popular weight loss/diabetes therapy Mounjaro in the country this March. The Danish drugmaker will offer Wegovy as a once-weekly injection in five dosage strengths: 0.25 mg, 0.5 mg, 1 mg, 1.75 mg, and 2.4 mg. Approved in India for chronic weight management and reducing the risk of major cardiovascular events, the drug will be priced at 4,366 rupees ($50.71) for the first three doses. Monthly treatment will cost 17,345 rupees, while higher doses are priced between 24,280 rupees and 26,015 rupees per month. The drug is under distribution and will be in pharmacies by end of the month, _Reuters_ reported, quoting Vikrant Shrotriya, Novo Nordisk's India managing director.

Eli Lilly (NYSE:LLY [https://seekingalpha.com/symbol/LLY]), which operates a duopoly in the weight loss drug market with Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]), had introduced Mounjaro 2.5 mg and 5 mg vials at 3,500 rupees and 4,375 rupees, respectively. NVO shares were up 1.95% premarket. MORE ON NOVO NORDISK, ELI LILLY * Eli Lilly: It Is A Bet On Human Longevity [https://seekingalpha.com/article/4796727-eli-lilly-it-is-a-bet-on-human-longevity] * Novo Nordisk News Is Bad News For Hims & Hers As GLP-1 Collaboration Terminated - Expect Volatility [https://seekingalpha.com/article/4796618-novo-nordisk-news-bad-for-hims-hers-health-glp-1-collaboration-terminated-expect-volatility] * Lilly ADA Investor Presentation [https://seekingalpha.com/article/4796490-lilly-ada-investor-presentation] * Market Voices: Novo slams Hims, Fed rates, Trump Media, drug tariffs [https://seekingalpha.com/news/4461079-market-voices-novo-slams-hims-fed-rates-trump-media-drug-tariffs] * Eli Lilly drug bimagrumab saves muscle mass when added to Novo's Wegovy [https://seekingalpha.com/news/4460981-eli-lilly-drug-bimagrumab-saves-muscle-mass-when-added-novo-nordisk-wegovy]

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.